Insights

Gathering insights about caba…

Similar companies to caba

caba Tech Stack

caba uses 8 technology products and services including UserWay, Linkedin Insight Tag, Cloudflare CDN, and more. Explore caba's tech stack below.

UserWay
Accessibility
Linkedin Insight Tag
Analytics
Cloudflare CDN
Content Delivery Network
jQuery
Javascript Libraries
PHP
Programming Languages
HSTS
Security
Cloudflare Bot Management
Security
Twitter
Widgets

Media & News

Cabaletta Bio, Inc. (CABA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Cabaletta Bio, Inc. (CABA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Dec 03, 2025 | seekingalpha.com
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient use All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who would have met key criteria for the registrational cohort met the registrational, 16-week primary endpoint Planned BLA submission for rese-cel in 2027 based on 14-patient, single-arm DM/ASyS registrational cohort initiating enrollment this quarter within the RESET-Myositis™ trial FDA alignment on additional registrational cohort designs for RESET-SSc™ and RESET-SLE™ anticipated by year-end 2025 PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. “Our team continued to execute with discipline and precision to extend our leadership through the RESET™ clinical development program.
Nov 10, 2025 | www.globenewswire.com
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
PHILADELPHIA, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences in November and December:
Nov 04, 2025 | www.globenewswire.com
Cabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Up 85.8% in October
Cabaletta Bio, Inc. (NASDAQ: CABA - Get Free Report) saw a significant growth in short interest in the month of October. As of October 15th, there was short interest totaling 11,220,000 shares, a growth of 85.8% from the September 30th total of 6,040,000 shares. Currently, 13.8% of the shares of the stock are short sold. Based
Nov 03, 2025 | www.defenseworld.net
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses with no immunomodulators – – Myositis registrational trial being initiated this quarter with a planned cohort of 14 DM/ASyS patients and a 16-week primary endpoint – moderate or major TIS while off immunomodulators and on no or low-dose steroids – consistent with FDA alignment on key trial parameters – – All systemic sclerosis patients with sufficient follow-up demonstrated ongoing, transformative clinical responses off all immunomodulators and steroids – – Seven of 8 lupus patients with sufficient follow-up achieved DORIS or renal response; RESET-SLE™ trial expanding to include a no preconditioning cohort with initial clinical data expected in 2026 – – 76 patients enrolled at 77 clinical trial sites globally as of October 24, 2025 – PHILADELPHIA, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced positive clinical data and development updates across the RESET-Myositis™, RESET-SSc™ and RESET-SLE trials evaluating rese-cel (resecabtagene autoleucel, formerly known as CABA-201). These data are being presented in multiple oral and poster presentations at the ongoing American College of Rheumatology (ACR) Convergence 2025, which is being held at the McCormick Place Convention Center in Chicago, Illinois, from October 24-29, 2025.
Oct 27, 2025 | www.globenewswire.com
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant
– Gavel brings highly relevant CAR T experience from Legend Biotech where he led the launch and commercialization of CARVYKTI® from 2018 until 2025 – PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced the appointment of Steve Gavel as Chief Commercial Officer, effective immediately. In his role, Mr.
Oct 14, 2025 | www.globenewswire.com
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress
– Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory patients; all three patients remained off immunomodulators since infusion and are off or tapering steroids as of the data cut-off –
Oct 09, 2025 | www.globenewswire.com

caba's Email Address Formats

caba uses at least 1 format(s):

caba Email Formats	Example	Percentage
First.Last@caba.org.uk	John.Doe@caba.org.uk	94%
First.MiddleLast@caba.org.uk	John.MichaelDoe@caba.org.uk	3%
Last@caba.org.uk	Doe@caba.org.uk	2%
FirstLast@caba.org.uk	JohnDoe@caba.org.uk	1%

Frequently Asked Questions

What is caba's phone number?

You can contact caba's main corporate office by phone at

+44-1788-55****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is caba's stock symbol?

caba is a publicly traded company; the company's stock symbol is CABA.

What is caba's official website and social media links?

caba's official website is caba.org.uk and has social profiles on LinkedIn.

What is caba's NAICS code?

caba's NAICS code is 813 - Religious, Grantmaking, Civic, Professional, and Similar Organizations.

How many employees does caba have currently?

As of December 2025, caba has approximately 502 employees across 5 continents, including EuropeSouth AmericaAsia. Key team members include Chief Executive Officer: C. H.Ceo: C. H.Head Of People And Culture: S. D.. Explore caba's employee directory with LeadIQ.

What industry does caba belong to?

caba operates in the Non-profit Organizations industry.

What technology does caba use?

caba's tech stack includes UserWayLinkedin Insight TagCloudflare CDNjQueryPHPHSTSCloudflare Bot ManagementTwitter.

What is caba's email format?

caba's email format typically follows the pattern of First.Last@caba.org.uk. Find more caba email formats with LeadIQ.

When was caba founded?

caba was founded in 1886.

caba

Q: What is caba's official website and social media links?

caba's official website is caba.org.uk. caba has social profiles on LinkedIn.

Q: How many employees does caba have currently?

caba has approximately 502 employees.

Q: What technology does caba use?

caba's tech stack includes UserWay, OWL Carousel, ShareThis, MobX, Dotdigital.

Non-profit OrganizationsEngland, United Kingdom501-1000 Employees

It might be today. It might be the day you never saw coming. But if worries about your money or your health become overwhelming caba is here. Our one-to-one support, practical advice and helpful resources are there if you need them, today or any day.

If you’re an existing or former ICAEW member, an ACA student, or a close family dependent, we’re here for you.

Company Overview

Phone number: +44-1788-55****
Website: caba.org.uk
Stock Symbol: CABA
NAICS Code: 813 - Religious, Grantmaking, Civic, Professional, and Similar Organizations
Founded: 1886
Employees: 501-1000

Media & News

Funding & Financials

$25M$50M
caba's revenue is estimated to be in the range of $25M$50M

Funding & Financials

$25M$50M
caba's revenue is estimated to be in the range of $25M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to caba

NFPA

Applied Communications Group

ACCA Pakistan

IFMA

RSES

ANSi

ASHRAE

caba Tech Stack

Media & News

Cabaletta Bio, Inc. (CABA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December

Cabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Up 85.8% in October

Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025

Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant

Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress

caba's Email Address Formats

Frequently Asked Questions

What is caba's phone number?

What is caba's stock symbol?

What is caba's official website and social media links?

What is caba's NAICS code?

How many employees does caba have currently?

What industry does caba belong to?

What technology does caba use?

What is caba's email format?

When was caba founded?

caba

Company Overview

Media & News

Cabaletta Bio, Inc. (CABA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?